DIP Episode 648 - USMLE Step 2/3 Rapid Review Series 135

Source / episode info

**Episode:**648
**Title:**DIP Ep 648: USMLE Step 2/3 Rapid Review Series 135
**Published:**2026-04-15
Source:Episode page

One-liner

This rapid review covers complex multi-system disorders including Lesch-Nyhan Syndrome (HGPRT defect), Lynch Syndrome (MMR deficiency/MSI), the clinical uses of somatostatin analogs like Octreotide for various syndromes, and the pathophysiology and management of thalassemia.

High-yield summary

Lesch-Nyhan Syndrome: Caused by a defect in HGPRT (Hypoxanthine Guanine Phosphoribosyltransferase), leading to purine overproduction, hyperuricemia, and gout/tophi formation; classic triad includes self-mutilating behavior.
Lynch Syndrome (HNPCC): An autosomal dominant hereditary cancer syndrome caused by defects in Mismatch Repair (MMR) genes ({MLH1}, {MSH2}, {MSH6}, {PMS2}), resulting in microsatellite instability and high risk of CRC, endometrial, and ovarian cancers.
Thalassemia: Characterized by reduced synthesis of specific globin chains (e.g., -thalassemia); leads to microcytic, hypochromic anemia with target cells; chronic hemolysis causes iron overload requiring chelation therapy.
Calcineurin Inhibitors (Octreotide/Lanreotide): Used as somatostatin analogs to decrease hormone production at the source in conditions like VIPoma, Carcinoid Syndrome, and for rapid reduction of portal pressure in variceal bleeding.

Learning objectives

Differentiate between various genetic disorders causing metabolic or hematological issues (e.g., LNS vs. Thalassemia).
Recognize the clinical presentation and screening guidelines for hereditary cancer syndromes (Lynch Syndrome).
Understand the mechanism of action and appropriate indications for somatostatin analogs in GI pathology.
Interpret peripheral blood smear findings (target cells, microcytosis) and hemoglobin electrophoresis results in thalassemia.

Board exam buzzwords

Condition	Key Finding	Association	Board Exam Tip
Lesch-Nyhan Syndrome	Self-mutilating behavior; Hyperuricemia	HGPRT deficiency; Purine salvage pathway defect	Remember the X-linked recessive nature and the primary treatment (Allopurinol).
Lynch Syndrome (HNPCC)	Early-onset CRC, Endometrial cancer	Mismatch Repair Genes ({MLH1}, {MSH2}); Microsatellite Instability (MSI)	Screening must start early (age 20) and be frequent (every 1–2 years).
Thalassemia	Microcytic, hypochromic anemia; Target cells	Globin chain deficiency ( or )	Always check for iron overload/chelation requirements in chronic hemolytic states.
Octreotide/Somatostatin Analog	Decreased hormone secretion at the source	VIPoma, Carcinoid Syndrome, Portal Hypertension	Used to rapidly stabilize bleeding and reduce excessive hormonal output.

Source / episode info

One-liner

High-yield summary

Learning objectives

Board exam buzzwords

Rapid review table